RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Yangarra Resources Ltd. (TSX: YGR) is a junior oil and gas company engaged in the exploration, development and production of natural gas and oil with operations in Western Canada, with a main focus on the Cardium in Central Alberta, where the Company has an extensive infrastructure and landholdings.
Revenue Mix
Business Segment
Investment Rationale
Source: Refinitiv (Thomson Reuters)
Source: Refinitiv, Thomson Reuters
Technical Price Chart (as on February 02, 2021). Source: Refinitiv (Thomson Reuters)
Financial Highlights: Q3FY20 (figures in Canadian Dollar “CAD”)
Source: Company Filing
Source: Company Filing.
Source: Company Filing
Top-10 Shareholders
The top 10 shareholders have been highlighted in the table, which together forms around 16.11% of the total shareholding. Gordon A Bowerman and James G Evaskevich hold the maximum shares in the company at 4.3% and 3.1%, respectively. Institutional ownership in the company stood at 4.23%, and strategic ownership stood at 14.23%.
Source: Refinitiv (Thomson Reuters)
Valuation Methodology (Illustrative): EV to EBITDA based Valuation Metrics
Note: All forecasted figures have been taken from Refinitiv (Thomson Reuters)
Peer Comparison
Source: Refinitiv (Thomson Reuters)
Stock Recommendation: With capital efficiencies improving materially, and the strengthening of natural gas prices and more stability in oil prices, the company is well positioned to capitalize on it.
Despite a lower performance on a YoY basis, the company has recorded solid recovery in margin profile on a sequential-quarter basis. The company’s gross margin during the third quarter of FY20 stood at 79.2%, improved by 940bps against the sequential quarter. EBITDA surged to 71.7% in the same quarter from 51% reported in the previous quarter, implies a jump of 20.7 percentage points. Operating margin surged to 34.6% from 3.4% in the second quarter of 2020, leapt up 31.2 percentage point. Net margin returned to positive 3% against negative 17.5% reported in the previous quarter. The improvement in the company’s margin profile was primarily driven by a solid recovery in the oil prices in the third quarter of 2020.
Going forward, we expect a gradual recovery in oil demand as a number of vaccines got approval from various regulatory bodies and economic activities are coming back on track. Improved oil prices on the back of demand recovery would result in better financial performance for the group.
Moreover, the recent insiders buying activities shows that they are bullish on the group’s future performance. And, technical indicators are also moving in favor of the bulls, with stock traded above the crucial short-term as well as long-term support levels.
Therefore, based on the above rationale and valuation, we recommend a “Speculative Buy” rating at the closing price of CAD 0.86 on February 02, 2021.
Source: Refinitiv (Thomson Reuters)
*Recommendation is valid at February 3, 2021 price as well.
Disclaimer
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.